The IASLC annual awards were presented during the World Conference on Lung Cancer (WCLC). These awards recognise individuals who have made significant contributions to the development of clinical and research aspects in various areas related to lung cancer, such as cancer staging (systems to determine the extent of tumours), pathology, and tobacco control.

Dr. Montse Sanchez-Cespedes, head of the Cancer Genetics Research Group at the Josep Carreras Institute, has been distinguished for her key contributions to understanding some of the genetic mechanisms involved in the onset of lung cancer, such as mutations in tumour suppressor genes, which have antitumour effects. In particular, her research on the SMARCA4 and STK11 genes has garnered significant interest in recent years. Indeed, her work on the inactivation of SMARCA4 has contributed to the development of a therapeutic approach for tumours with mutations in this gene.

Recently, Dr. Sanchez-Cespedes' research group has focused on gaining a better understanding of how certain mutations in tumours enable them to evade attacks from the immune system. This new knowledge will pave the way for the development of novel targeted therapies and immuno-oncology treatments for lung cancer, after already demonstrating great efficacy in the fight against haematological tumours such as leukaemia.

This latest recognition of Dr. Sanchez-Cespedes' work reaffirms the multidisciplinary commitment of the Josep Carreras Leukaemia Research Institute and strengthens our relentless fight against cancer.